SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-------------------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 3, 2003
VAXGEN, INC.
(Exact name of Registrant as Specified in its Charter)
DELAWARE 0-26483 94-3236309
(State or other jurisdiction of (Commission (I.R.S. Employer
Identification Number) File Number) incorporation or organization)
1000 MARINA BLVD., SUITE 200 BRISBANE, CALIFORNIA 94005
(Address of Principal Administrative Offices)
Registrants Telephone Number, Including Area Code: (650) 624-1000
Item 5. Other Events.
On September 3, 2003, VaxGen, Inc. issued a statement that it had signed a
binding letter of intent with the Health Protection Agency (HPA) for England and
Wales to negotiate terms under which VaxGen would license U.K. rights to, and
transfer technology for, its recombinant anthrax vaccine candidate. The
agreement would give HPA the right to manufacture the vaccine in the United
Kingdom as well as to market the vaccine in the United Kingdom and possibly
other territories.
Item 7. Financial Statements and Exhibits.
(c) Exhibits.
Exhibit No. Description
- ----------- -----------
99.1 Press release issued by VaxGen, Inc. on September 3, 2003.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
VaxGen, Inc.
(Registrant)
Dated: September 4, 2003 By: /s/ Carter A. Lee
------------------------------
Carter Lee
Senior Vice President
Finance & Administration